Qualigen Therapeutics Statistics Share Statistics Qualigen Therapeutics has 1.69M
shares outstanding. The number of shares has increased by 129.74%
in one year.
Shares Outstanding 1.69M Shares Change (YoY) 129.74% Shares Change (QoQ) 129.74% Owned by Institutions (%) 5.66% Shares Floating 1.7M Failed to Deliver (FTD) Shares 182 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 39.49K, so 2.33% of the outstanding
shares have been sold short.
Short Interest 39.49K Short % of Shares Out 2.33% Short % of Float 2.33% Short Ratio (days to cover) 1.03
Valuation Ratios The PE ratio is -0.25 and the forward
PE ratio is null.
Qualigen Therapeutics's PEG ratio is
0.
PE Ratio -0.25 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 0.57 P/FCF Ratio -0.24 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Qualigen Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.33,
with a Debt / Equity ratio of 0.
Current Ratio 2.33 Quick Ratio 2.33 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage -6.34
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.54M Employee Count 4 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 6.33K Effective Tax Rate -0.1%
Stock Price Statistics The stock price has increased by -36.84% in the
last 52 weeks. The beta is 0.33, so Qualigen Therapeutics's
price volatility has been higher than the market average.
Beta 0.33 52-Week Price Change -36.84% 50-Day Moving Average 2.65 200-Day Moving Average 3.34 Relative Strength Index (RSI) 63.97 Average Volume (20 Days) 2,357,828
Income Statement
Revenue n/a Gross Profit n/a Operating Income -5.76M Net Income -6.16M EBITDA -5.24M EBIT -5.24M Earnings Per Share (EPS) -17.28
Full Income Statement Balance Sheet The company has 1.17M in cash and 0 in
debt, giving a net cash position of 1.17M.
Cash & Cash Equivalents 1.17M Total Debt n/a Net Cash n/a Retained Earnings -123.06M Total Assets 3.96M Working Capital -1.65M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -6.33M
and capital expenditures 0, giving a free cash flow of -6.33M.
Operating Cash Flow -6.33M Capital Expenditures n/a Free Cash Flow -6.33M FCF Per Share -17.5
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields QLGN does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for QLGN.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Nov 5, 2024. It was a
backward
split with a ratio of 1:50.
Last Split Date Nov 5, 2024 Split Type backward Split Ratio 1:50
Scores Altman Z-Score -49.34 Piotroski F-Score 3
